Immunotherapy for Hodgkin’s lymphoma

Healthcare professionals
Immunotherapy uses a person’s immune system to fight against cancer. Research into its effectiveness and long-term outcomes is currently ongoing.
According to the
The
Research is currently investigating the effect of these drugs earlier in cancer treatment and alongside other treatment types.
A 2024 study compared brentuximab vedotin with nivolumab in 970 people ages 12 years and older with stage III or IV classic Hodgkin’s lymphoma.
All study participants received treatment with doxorubicin, vinblastine, and dacarbazine. The researchers then randomly assigned treatment with nivolumab or brentuximab vedotin.
The study concluded that nivolumab treatment improved progression-free survival at a better rate than brentuximab vedotin. After two years, progression-free survival rates were 92% for nivolumab and 83% for brentuximab vedotin.
Healthcare professionals
The frequency of treatment with immunotherapy will depend on the extent of a person’s cancer and the type of immunotherapy they have.
Like any treatment, immunotherapy can cause side effects. According to the
- fatigue
- fever
- nausea
- skin rashes
- constipation
Side effects may vary from person to person and may differ depending on the drug. People should tell their healthcare team if they experience any side effects.
Anyone with Hodgkin’s lymphoma who wants to learn more about immunotherapy and whether it is suitable for them can speak with their healthcare team. In some cases, a doctor may want to try other treatments first.
link